Trends in Molecular Medicine
ReviewDeveloping c-MET pathway inhibitors for cancer therapy: progress and challenges
Introduction
Significant progress has been made towards developing target-based cancer therapies over the past decade. Numerous agents have been approved that are designed to block specific signaling pathways important for tumor formation, progression, dissemination and/or angiogenesis [1]. Despite the remarkable success, most approved agents do not cure patients. In addition, pre-existing resistance to these agents is readily detectable in many intent-to-treat (ITT) patients. Furthermore, most patients who initially respond to the treatments nevertheless develop resistance, and the tumors that emerge are often more aggressive and difficult to treat. Although mechanisms for resistance might vary, one major problem is the extremely complex nature of tumor cells because of their genetic heterogeneity and instability. Recent genomic and biochemical studies indicate that even in tumors of the same tissue origin there are many differences that potentially contribute to the disease 2, 3. Thus, the ultimate success in controlling most if not all cancers requires the application of multiple agents that effectively inhibit different pro-cancer mechanisms.
Oncogenic protein kinases represent a class of biologically important targets for cancer intervention. Among them, c-MET and its ligand hepatocyte growth factor (HGF) have recently attracted considerable attention. c-MET belongs to a subfamily of receptor tyrosine kinases (RTKs), which also includes RON and SEA [4]. HGF is the only known high affinity ligand for c-MET. The mature c-MET receptor is structurally distinct from most other RTKs and exists as a heterodimer containing an extracellular α chain and a transmembrane β chain, which anchors the kinase domain in its cytoplasmic portion (Figure 1). Detailed descriptions of the structural domains and their functions with respect to c-MET and HGF can be found elsewhere 4, 5, 6.
In normal physiology, the c-MET pathway regulates many cellular responses including cell proliferation, survival, motility, invasion and morphogenesis 4, 6. Upon activation via HGF binding and/or receptor overexpression, c-MET autophosphorylates, recruits adaptor proteins and activates multiple downstream effector proteins and cascades, as illustrated in Figure 1. The participation of these adaptors and effectors is essential for c-MET to exert its full biological functions [7]. HGF and c-MET are expressed in various tissues, but are usually restricted to cells of epithelial and mesenchymal origin 4, 6. Mouse genetic studies support the essential roles of both HGF and c-MET in normal embryonic development and organogenesis [4]. The functions of HGF and c-MET in adults, however, are more restricted, and are involved mainly in tissue damage repair and regeneration 4, 5, 8.
Since the discovery of c-MET and HGF, much research interest has focused on their roles in cancer. The c-MET pathway is one of the most frequently dysregulated pathways in human cancer, and aberrant c-MET signaling has been documented in most solid tumors and hematological malignancies 4, 6. The strongest evidence that links c-MET directly to cancer came from the original discovery of missense c-MET mutations in all patients with hereditary papillary renal cell carcinomas (PRCC) and a small subset (13%) of sporadic PRCC samples 4, 6. Trisomy of chromosome 7, where both HGF and c-MET genes are located, also occurs frequently in PRCC. Subsequently, c-MET mutations were reported in many other cancers, including gastric, head and neck, liver, ovarian, non-small cell lung (NSCL) and thyroid cancers, as well as in metastases of some of these cancers 6, 7, 9. The tumorigenic potential of several c-MET mutants was confirmed in preclinical models 10, 11. In addition, c-MET is also commonly activated via receptor overexpression and amplification, as well as by elevated HGF levels. c-MET has been shown to be frequently overexpressed or amplified in many cancers, including brain, colorectal, gastric, lung, head and neck and stomach cancers 6, 7, 12, 13, 14, and circulating HGF levels are elevated in most cancers 4, 15, 16. Both amplifications have been associated with poor clinical outcomes 6, 7, 14, 15, 16, 17, 18, 19, underscoring the importance of increased c-MET signaling in these cancer types.
The involvement of HGF/c-MET in cancer has also been supported by more recent data. For instance, a somatic mutation/polymorphism in the HGF promoter region, which results in increased HGF expression, was recently identified in breast cancer patients, with significant prevalence in patients of African American (51%) and European descent (15%) [20]. Moreover, individuals carrying the mutation are substantially younger and present with a more aggressive disease, underscoring its potential as a genetic marker for identifying high risk individuals. Upon careful examination of tumor biopsies, it was also found that not only is c-MET expressed in solid tumors, but HGF is widely detected in the intratumoral spaces of solid tumors, indicating a potential role of an HGF autocrine/paracrine loop in solid tumors [21]. In addition, the recent identification of upregulated metastasis-associated in colon cancer-1 (MACC1), which plays a crucial role in promoting tumor metastasis by controlling c-MET transcription, further supports the role of c-MET in colon cancer [22].
c-MET signaling can also be modulated by other proteins/enzymes, including RON, EGFRs, α6β4 integrin, plexin B1, CD44 and FAS (Figure 1) 6, 7, 23. The interactive relationships between c-MET and these proteins have been corroborated by numerous studies either on an individual protein basis or a systematic, global scale 7, 24. Although the exact mechanisms are still under investigation, the complex network in which the c-MET receptor interacts with these proteins, many of which are known to have important roles in cancer, is further evidence that the HGF/c-MET axis is a key regulator in cancer.
An activated c-MET promotes tumor cell growth, survival, migration and invasion, as well as tumor angiogenesis 4, 6, 25. The historical evidence that validates the c-MET pathway as a cancer target mainly comes from the data generated by two complementary approaches. First, the overexpression of HGF and/or c-MET (wild type or mutants) confers a transforming phenotype in cell lines, whereas mice expressing HGF and/or c-MET as a transgene(s) develop different tumors and metastatic lesions 4, 6. Second, the downregulation of HGF or c-MET expression or inhibition of c-MET kinase in HGF/c-MET-driven tumor cells significantly decreases cell growth, survival, motility, migration and invasion in vitro, and reduces tumorigenic and metastatic potential in vivo 6, 7. Recent studies using pharmaceutically-developed monoclonal antibodies (mAbs) and small molecule c-MET tyrosine kinase inhibitors (TKIs) further support the therapeutic potential of c-MET inhibition, as we will discuss in greater detail.
In summary, the c-MET pathway has been strongly implicated in a variety of human malignancies. The preclinical data that support therapeutic approaches for c-MET inhibition in cancer are both extensive and convincing, offering a compelling rationale for the further exploration of targeting c-MET in patients.
Section snippets
c-MET pathway inhibitors in development
Given the strong connection of abnormal c-MET signaling to human cancers, TKIs and therapeutic mAbs that antagonize c-MET activation have been actively pursued by pharmaceutical companies (Figure 1). To date, at least 16 such agents have been or are being evaluated in the clinic (Table 1). These agents exhibit remarkably different properties with respect to potency, selectivity, pharmacokinetic (PK) properties and toxicity profile. As the clinical trials with these agents progress, promising
Lessons learned from the clinical studies of the c-MET pathway inhibitors
Despite the enthusiasm generated by the clinical evaluation of some c-MET pathway inhibitors, it is still too early to conclude if or where these agents will be useful as anticancer agents. Careful examination of the properties of the studied agents and the emerging data will shed some light on where the opportunities are and what challenges lie ahead.
Based on the clinical data obtained with the selective inhibitors to date, it remains unclear how effective targeting the c-MET pathway is as a
Concluding remarks
The historical and emerging evidence strongly implicates abnormal c-MET signaling in many cancers, supporting targeting this pathway for cancer intervention. Thus far, over a dozen c-MET pathway inhibitors have been studied in the clinic, and significant progress has been achieved. Several inhibitors are entering late-stage trials after being taken to the clinic only a short time ago. However, as the trials progress many questions and challenges, detailed in Box 1, will also arise and need to
Disclosure statement
X.L., R.C.N. and P.A.S. are employees of Incyte Corporation and currently involved in the clinical development of INCB28060.
References (78)
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
Cell
(2007)c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
Cancer Lett.
(2005)c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases
Cancer Lett.
(2008)Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome
Cancer Lett.
(2007)Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin
Hum Pathol.
(2009)Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia
Lancet Oncol.
(2007)MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients
Ann Oncol.
(2009)- et al.
Novel agents on the horizon for cancer therapy
CA Cancer J Clin.
(2009) Patterns of somatic mutation in human cancer genomes
Nature
(2007)Met, metastasis, motility and more
Nat Rev Mol Cell Biol.
(2003)
Translational research to identify clinical applications of hepatocyte growth factor
Hepatol Res.
Targeting the c-MET signaling pathway for cancer therapy
Expert Opin Investig Drugs.
c-Met confers protection against chronic liver tissue damage and fibrosis progression after bile duct ligation in mice
Gastroenterology
Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele
Proc Natl Acad Sci USA
Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer
Proc Natl Acad Sci USA
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma
Cancer Res.
HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer
Clin Cancer Res.
Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer
Cancer Sci.
Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients
Int J Cancer
Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer
Clin Cancer Res.
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients
J Clin Oncol.
Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer
J Clin Invest.
Expression and mutational analysis of MET in human solid cancers
Genes Chromosomes Cancer
MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis
Nat Med.
The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer
Dis Colon Rectum.
Signaling networks assembled by oncogenic EGFR and c-Met
Proc Natl Acad Sci USA
The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis
BMB Rep.
Inhibition of HGF/c-MET pathway by ARQ197: characterization of pharmacodynamic markers in vitro and in vivo
Final results: A dose escalation phase I study of ARQ197, a selective c-Met inhibitor, in patients with metastatic solid tumors
Final results of a pharmacokinetic (PK) and pharmacodynamic (PD) phase I trial of ARQ 197 incorporating dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) studies investigating the antiangiogenic activity of selective c-Met inhibition
Phase I dose escalation trial (ARQ197-111) evaluating combination of selective c-Met inhibitor ARQ197 and erlotinib
Preliminary results from a phase II study of ARQ197 in patients with microphthalmia transcription factor family (MiT)-associated tumors
An orally available small-molecule inhibitor of c-MET, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
Cancer Res.
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
Mol Cancer Ther.
Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors
Biochemistry
Clinical activity observed in a phase I dose escalation trial of an oral c-Met and ALK inhibitor, PF-02341066
JNJ-38877605: a selective Met kinase inhibitor inducing regression of Met-driven tumor models
Discovery and characterization of INCB028060, a novel, potent and selective Met RTK inhibitor for cancer treatment
Cited by (162)
Development of a novel <sup>18</sup>F-labeled small molecule probe for PET imaging of mesenchymal epithelial transition receptor expression
2024, European Journal of Nuclear Medicine and Molecular ImagingProgress of antibody–drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies
2024, Drug Delivery and Translational Research